Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients

NCT00520260 Phase 4 COMPLETED

To compare bromfenac 0.09% and ketorolac 0.4% when used concomitantly with cyclosporine ophthalmic emulsion 0.05% in improving patient comfort during the induction phase of treatment for chronic dry eye disease

Details

Lead sponsor	Florida Eye Microsurgical Institute
Phase	Phase 4
Status	COMPLETED
Enrolment	42
Start date	2007-08
Completion	2008-08

Conditions

• Dry Eye Disease
• Ocular Comfort

Interventions

• bromfenac
• ketorolac

Primary outcomes

• Ocular comfort — six weeks

Countries

United States